15.45

2.59% 0.39

After Hours: 15.70 0.25 +1.62%

Greenwich Lifesciences Inc (GLSI)

Overview News Price History Financials Discussions Forecast

Greenwich Lifesciences Inc stock is traded at $15.45, with a volume of 74,805. It is up +2.59% in the last 24 hours and down -0.64% over the past month. Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Previous Close:

$15.06

Open:

$15.33

24h Volume:

74,805

Relative Volume:

0.53

Market Cap:

$226.78M

Revenue:

Net Income/Loss:

$-21.76M

P/E Ratio:

-9.9813

EPS:

-1.5479

Net Cash Flow:

$-12.78M

1W Performance:

-3.13%

1M Performance:

-0.64%

6M Performance:

-41.85%

1Y Performance:

+35.29%

1-Day Range:

$15.09

$15.60

1-Week Range:

$14.46

$16.34

52-Week Range:

$7.78

$34.10

Greenwich Lifesciences Inc Stock (GLSI) Company Profile

Name

Greenwich Lifesciences Inc

Sector

Healthcare (1069)

Industry

Biotechnology (595)

Phone

203-434-3290

Address

3992 BLUEBONNET DR, BUILDING 14, STAFFORD

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

GLSI's Discussions on Twitter

Compare GLSI vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLSI Greenwich Lifesciences Inc	15.45	226.78M	0	-21.76M	-12.78M	-1.5479
VRTX Vertex Pharmaceuticals Inc	515.44	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	781.49	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.39	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	143.97	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.77	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-25	Initiated	Noble Capital Markets	Outperform
Sep-01-21	Initiated	H.C. Wainwright	Buy

Greenwich Lifesciences Inc Stock (GLSI) Latest News

Sep 11, 2026

Greenwich Lifesciences Stock Price Forecast. Should You Buy GLSI? - StockInvest.us

Sep 05, 2026

Sep 01, 2026

One Greenwich LifeSciences Insider Raised Their Stake In The Previous Year - simplywall.st

Sep 01, 2026

Greenwich LifeSciences (GLSI) Slips 1.40% to $14.74, Holds Above Key SupportStock Picks - dars.gov.et

Sep 01, 2026

Aug 31, 2026

Understanding the Setup: (GLSI) and Scalable Risk - Stock Traders Daily

Aug 31, 2026

Aug 21, 2026

Why is Greenwich LifeSciences stock rallying today? - Investing.com

Aug 21, 2026

Aug 19, 2026

Greenwich (GLSI) Earnings Check: EPS Misses Its Estimate under the Current Snapshot; Post-Earnings Trading: The Share Price Sheds 0.69% on the DayAnnual Financial Report - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Greenwich Lifesciences Inc (NASDAQ: GLSI) Share Price, GLSI Stock News, GLSI Share Price & Updates - Kalkine

Aug 18, 2026

Aug 14, 2026

GLSI Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage R&D InvestmentEarnings Revision Downgrade - vinanet.vn

Aug 14, 2026

Aug 12, 2026

Greenwich Lifesciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Aug 11, 2026

Greenwich LifeSciences (NASDAQ:GLSI) Posts Quarterly Earnings Results - MarketBeat

Aug 11, 2026

Greenwich LifeSciences 2Q 2026: Revenue $0 Net loss $(3.95M), EPS $(0.27) — 10-Q Summary - TradingView

Aug 11, 2026

Greenwich LifeSciences | 10-Q: Q2 2026 Earnings Report - Moomoo

Aug 11, 2026